Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017

Data to be presented in three oral presentations and two poster presentations

CARMIEL, Israel, Feb. 13, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 13^th Annual WORLDSymposium™ 2017.  The details are as follows:

13th Annual WORLDSymposium™ 2017
February 13 – 17, 2017
Manchester Grand Hyatt, San Diego, CA

Oral Presentations:

“Characterization of a chemically modified plant cell culture expressed human α-galactosidase-A enzyme for treatment of Fabry disease” to be presented by Dr. Yoseph Shaaltiel, the Company’s Executive Vice President, Research & Development.  The oral presentation is scheduled for 4:00 PM PT on Tuesday, February 14, 2017.

“One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy” to be presented by Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease.  The oral presentation is scheduled for 3:45 PM PT on Thursday, February 16, 2017.

“PRX-102 for treating Fabry disease – immunogenicity and PK results from a phase 1-2 study” to be presented by Prof. David Warnock, Professor of Nephrology at the University of Alabama Birmingham, Birmingham, Alabama.  The oral presentation is scheduled for 4:15 PM PT on Thursday, February 16, 2017.

Poster Presentations:

Poster #149: “One‐year follow up of Fabry disease patients treated by IV administration of a plant derived alpha‐Gal‐A enzyme: safety and efficacy,” to be presented by Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trials of pegunigalsidase alfa for the treatment of Fabry disease on Tuesday, February 14, 2017 (4:30-6:30 PM PT).

Poster #355: “PRX‐102 for treating Fabry disease ‐ immunogenicity and PK results from a phase 1‐2 study” to be presented by Prof. David Warnock of the University of Alabama Birmingham, Birmingham, Alabama, on Wednesday, February 15, 2017 (4:30-6:30 PM PT).

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx^®.  Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.  Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries.  Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.  Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.

Investor Contact

Marcy Nanus
The Trout Group, LLC
646-378-2927
[email protected]